Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research


  • Shoyo Shibata University of Tsukuba http://orcid.org/0000-0002-8152-7546
  • Koken Ozaki Graduate School of Business Sciences, Humanities, and Social Sciences, University of Tsukuba
  • Takeshi Suzuki Education Research Center for Pharmaceutical Sciences, Faculty of Pharmacy, Keio University




Japan, pharmaceutical industry, drug pricing, regulatory science, clinical development, marketing strategy


The Japanese pharmaceutical market is one of the largest in the world. The Japanese government has increasingly been trying to control rising health care costs, and as a result, pharmaceutical companies are expecting that fewer opportunities will be available to command a higher price based on higher levels of innovation; this will likely lead to decreased interest in research and development (R&D) activities. With this background, the purpose of this article is to review current perspectives for R&D by the Japanese pharmaceutical industry, and to discuss the limitations and challenges for further research from the regulatory science and management perspectives. Given the substantial amount of evidence of regulatory science and management perspectives from the pharmaceutical industry outside of Japan and the limited amount of evidence from inside of Japan, it is important to review perspectives focusing on the Japanese pharmaceutical industry in comparison with those from other countries to understand the complexities of the Japanese pharmaceutical market, as well as the limitations and challenges associated with increasing productivity.



Afuah, A. (2002). Mapping technological capabilities into product markets and competitive advantage: the case of cholesterol drugs. Strategic Management Journal, 23(2), 171-179. https://www.doi.org/10.1002/smj.221

Aggarwal, V. A. (2019). Resource congestion in alliance networks: How a firm's partners' partners influence the benefits of collaboration. Strategic Management Journal, 41(4), 627-655. https://www.doi.org/10.1002/smj.3109

Aitken, M., Kleinrock, M., Simorellis, A., & Nass, D. (2019). The Global Use of Medicine in 2019 and Outlook to 2023: Forecasts and Areas to Watch. IQVIA Institute.

Alt, S., & Helmstadter, A. (2018). Market entry, power, pharmacokinetics: what makes a successful drug innovation? Drug Discovery Today, 23(2), 208-212. https://www.doi.org/10.1016/j.drudis.2017.09.009

Aoi, M., & Nakamura, H. (2003). Changes in external environments in the U.S. drug market and the impacts on R&D oriented pharmaceutical companies: implications for the Japanese system and R&D oriented pharmaceutical companies (in Japanese). Iryo To Shakai, 13(2), 85-111.

Asakawa, K., & Nakamura, H. (2005). Co-evolution of innovation systems in Japan's pharmaceutical and biotechnology industries (in Japanese). Iryo To Shakai, 15(1), 1-15.

Asano, K., Uyama, Y., & Tohkin, M. (2018). Factors Affecting Drug-Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan. Clinical and Translational Science, 11(2), 182-188. https://www.doi.org/10.1111/cts.12520

Barber, B., IV., & Diestre, L. (2019). Pushing for speed or scope? Pharmaceutical lobbying and Food and Drug Administration drug review. Strategic Management Journal, 40(8), 1194-1218. https://www.doi.org/10.1002/smj.3021

Bardey, D., Bommier, A., & Jullien, B. (2010). Retail price regulation and innovation: Reference pricing in the pharmaceutical industry. Journal of Health Economics, 29(2), 303-316. https://www.doi.org/10.1016/j.jhealeco.2009.11.015

Berndt, E. R. (2000). International comparisons of pharmaceutical prices: what do we know, and what does it mean? Journal of Health Economics, 19(2), 283-287. https://www.doi.org/10.1016/s0167-6296(99)00043-0

Bierly, P., & Chakrabarti, A. (1996). Generic knowledge strategies in the U.S. pharmaceutical industry. Strategic Management Journal, 17(S2), 123-135. https://www.doi.org/10.1002/smj.4250171111

Brekke, K. R., Konigbauer, I., & Straume, O. R. (2007). Reference pricing of pharmaceuticals. Journal of Health Economics, 26(3), 613-642. https://www.doi.org/10.1016/j.jhealeco.2006.11.003

Chen, Y., & Schweitzer, S. O. (2008). Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region. Value in Health, 11(Suppl 1), S124-S129. https://www.doi.org/0.1111/j.1524-4733.2008.00376.x

Costa-Font, J., McGuire, A., & Varol, N. (2014). Price regulation and relative delays in generic drug adoption. Journal of Health Economics, 38, 1-9. https://www.doi.org/10.1016/j.jhealeco.2014.04.004

Danzon, P. M., & Chao, L. W. (2000). Cross-national price differences for pharmaceuticals: how large, and why? Journal of Health Economics, 19(2), 159-195. https://www.doi.org/10.1016/s0167-6296(99)00039-9

Danzon, P. M., Wang, Y. R., & Wang, L. (2005). The impact of price regulation on the launch delay of new drugs -- evidence from twenty-five major markets in the 1990s. Health Economics, 14(3), 269-292. https://www.doi.org/10.1002/hec.931

DiMasi, J. A., Reichert, J. M., Feldman, L., & Malins, A. (2013). Clinical approval success rates for investigational cancer drugs. Clinical Pharmacology & Therapeutics, 94(3), 329-335. https://www.doi.org/10.1038/clpt.2013.117

Eger, S., & Mahlich, J. C. (2014). Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Economics Review, 4(1), 23. https://www.doi.org/10.1186/s13561-014-0023-5

Fukuda, T., & Shiroiwa, T. (2019). Application of economic evaluation of pharmaceuticals and medical devices in Japan. Journal of the National Institute of Public Health, 68(1), 27-33.

Ghislandi, S. (2011). Competition and the reference pricing scheme for pharmaceuticals. Journal of Health Economics, 30(6), 1137-1149. https://www.doi.org/10.1016/j.jhealeco.2011.08.010

Goldsmith, A. D., & Varela, F. E. (2017). Fragmentation in the biopharmaceutical industry. Drug Discovery Today, 22(2), 433-439. https://www.doi.org/10.1016/j.drudis.2016.10.013

Golec, J., & Vernon, J. A. (2010). Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms. Pharmacoeconomics, 28(8), 615-628. https://www.doi.org/10.2165/11535580-000000000-00000

Golec, J., Hegde, S., & Vernon, J. A. (2010). Pharmaceutical R&D Spending and Threats of Price Regulation. Journal of Financial and Quantitative Analysis, 45(1), 239-264. https://www.doi.org/10.1017/S0022109009990512

Grabowski, H., & Vernon, J. (2000). The determinants of pharmaceutical research and development expenditures. Journal of Evolutionary Economics, 10(1), 201-215.

Gregson, N., Sparrowhawk, K., Mauskopf, J., & Paul, J. (2005). Pricing medicines: theory and practice, challenges and opportunities. Nature Reviews Drug Discovery, 4(2), 121-130. https://www.doi.org/10.1038/nrd1633

Guan, X., Wushouer, H., Yang, M., Han, S., Shi, L., Ross-Degnan, D., & Wagner, A. K. (2019). Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. BMJ Open, 9(11), e031658. https://www.doi.org/10.1136/bmjopen-2019-031658

Guler, I., & Nerkar, A. (2012). The impact of global and local cohesion on innovation in the pharmaceutical industry. Strategic Management Journal, 33(5), 535-549. https://www.doi.org/10.1002/smj.957

Harrison, R. K. (2016). Phase II and phase III failures: 2013-2015. Nature Reviews Drug Discovery, 15, 817-818. https://www.doi.org/10.1038/nrd.2016.184

Hasegawa, M. (2020). HTA system implemented in Japan. PharmacoEconomics & Outcomes News, 846, 15. https://www.doi.org/10.1007/s40274-020-6554-6

Hasegawa, M., Komoto, S., Shiroiwa, T., & Fukuda, T. (2020). Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System. Value in Health, 23(1), 43-51. https://www.doi.org/10.1016/j.jval.2019.10.005

Hashimoto, A., & Haneda, S. (2008). Measuring the change in R&D efficiency of the Japanese pharmaceutical industry. Research Policy, 37(10), 1829-1836. https://www.doi.org/10.1016/j.respol.2008.08.004

Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology, 32(1), 40-51. https://www.doi.org/10.1038/nbt.2786

Hirai, Y., Kinoshita, H., Kusama, M., Yasuda, K., Sugiyama, Y., & Ono, S. (2010). Delays in New Drug Applications in Japan and Industrial R&D Strategies. Clinical Pharmacology & Therapeutics, 87(2), 212-218. https://www.doi.org/10.1038/clpt.2009.215

Hirai, Y., Yamanaka, Y., Kusama, M., Ishibashi, T., Sugiyama, Y., & Ono, S. (2012). Analysis of the success rates of new drug development in Japan and the lag behind the U.S. Health Policy, 104(3), 241-246. https://www.doi.org/10.1016/j.healthpol.2011.11.008

Honig, P. K. (2014). Recent trends and success factors in reducing the lag time to approval of new drugs in Japan. Clinical Pharmacology & Therapeutics, 95(5), 467-469. https://www.doi.org/10.1038/clpt.2013.256

Ichimaru, K., Toyoshima, S., & Uyama, Y. (2010). PMDA's Challenge to Accelerate Clinical Development and Review of New Drugs in Japan. Clinical Pharmacology & Therapeutics, 88(4), 454-457. https://www.doi.org/10.1038/clpt.2010.190

Ide, H., Yasunaga, H., Imamura, T., & Ohe, K. (2007). Price differences between Japan and the U.S. for medical materials and how to reduce them. Health Policy, 82(1), 71-77. https://www.doi.org/10.1016/j.healthpol.2006.08.003

Ikegami, N., Ikeda, S., & Kawai, H. (1998). Why Medical Care Costs in Japan Have Increased Despite Declining Prices for Pharmaceuticals. PharmacoEconomics, 14(Suppl 1), 97-105. https://www.doi.org/10.2165/00019053-199814001-00012

Ito, K., & Lechevalier, S. (2010). Why some firms persistently out-perform others: investigating the interactions between innovation and exporting strategies. Industrial and Corporate Change, 19(6), 1997-2039. https://www.doi.org/10.1093/icc/dtq056

Kato, Y., Matsui, T., Hane, Y., Abe, J., Ueda, N., Sasaoka, S., Motooka, Y., Hatahira, H., Umetsu, R., & Nakamura, M. (2016). Analysis of new drug price calculation according to National Health Insurance (NHI) drug price list in Japan (in Japanese). Regulatory Science of Medical Products, 6(2), 171-183.

Kavusan, K., & Frankort, H. T. W. (2019). A behavioral theory of alliance portfolio reconfiguration: Evidence from pharmaceutical biotechnology. Strategic Management Journal, 40(10), 1668-1702. https://www.doi.org/10.1002/smj.3041

Kesselheim, A. S., & Avorn, J. (2013). The most transformative drugs of the past 25 years: a survey of physicians. Nature Reviews Drug Discovery, 12(6), 425-431. https://www.doi.org/10.1038/nrd3977

Kesselheim, A. S., Wang, B., & Avorn, J. (2013). Defining "Innovativeness" in Drug Development: A Systematic Review. Clinical Pharmacology & Therapeutics, 94(3), 336-348. https://www.doi.org/10.1038/clpt.2013.115

Kido, K., Matsumaru, N., & Tsukamoto, K. (2019). Health Technology Assessment in Japan: A Pharmaceutical Industry Perspective. Therapeutic Innovation & Regulatory Science, 53(4), 472-480. https://www.doi.org/10.1177/2168479018791136

Kneller, R. (2010). The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Reviews Drug Discovery, 9(11), 867-882. https://www.doi.org/10.1038/nrd3251

Koenig, P., & MacGarvie, M. (2011). Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe. Journal of Health Economics, 30(5), 950-965. https://www.doi.org/10.1016/j.jhealeco.2011.07.005

Kogure, S., Koyama, N., & Hidaka, S. (2017). Utilization of the Bridging Strategy for the Development of New Drugs in Oncology to Avoid Drug Lag. Journal of Clinical Pharmacology, 57(11), 1479-1490. https://www.doi.org/10.1002/jcph.951

Kogushi, K., Ogawa, T., & Ikeda, S. (2019). An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan. Expert Review of Pharmacoeconomics & Outcomes Research. https://www.doi.org/10.1080/14737167.2019.1665513

Kondo, H., Shimada, Y., & Ozawa, T. (2019). Promotion of Japan's participation in global clinical trials. Drug Discovery Today, 24(4), 939-942. https://www.doi.org/10.1016/j.drudis.2019.01.016

Kyle, M. K. (2007). Pharmaceutical Price Controls and Entry Strategies. The Review of Economics and Statistics, 89(1), 88-99.

Liu, Y-M., Yang, Y-H. K., & Hsieh, C-R. (2012). Regulation and competition in the Taiwanese pharmaceutical market under national health insurance. Journal of Health Economics, 31(3), 471-483. https://www.doi.org/10.1016/j.jhealeco.2012.03.003

Liu, G., Wu, E. Q., Ahn, J., Kamae, I., Xie, J., & Yang, H. (2020). The Development of Health Technology Assessment in Asia: Current Status and Future Trends. Value in Health Regional Issues, 21, 39-44. https://www.doi.org/10.1016/j.vhri.2019.08.472

Lu, J. W., & Beamish, P. W. (2004). International Diversification and Firm Performance: The S-curve Hypothesis. Academy of Management Journal, 47(4), 598-609. https://www.doi.org/10.5465/20159604

Macher, J. T., & Boerner, C. (2012). Technological development at the boundaries of the firm: a knowledge-based examination in drug development. Strategic Management Journal, 33(9), 1016-1036. https://www.doi.org/10.1002/smj.1956

Maeda, H., & Kurokawa, T. (2015a). Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? International Journal of Clinical Oncology, 20(6), 1072-1080. https://www.doi.org/10.1007/s10147-015-0825-4

Maeda, H., & Kurokawa, T. (2015b). Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States. The Journal of Clinical Pharmacology, 55(5), 481-489. https://www.doi.org/10.1002/jcph.458

Mahlich, J. C., & Roediger-Schluga, T. (2006). The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan. Review of Industrial Organization, 28(2), 145-164. https://www.doi.org/10.1007/s11151-006-0010-z

Matsushita, S., Tachibana, K., & Kondoh, M. (2019). The Clinical Innovation Network: a policy for promoting development of drugs and medical devices in Japan. Drug Discovery Today, 24(1), 4-8. https://www.doi.org/10.1016/j.drudis.2018.05.026

Miller, K., L., & Lanthier, M. (2015). Regulatory watch: Innovation in biologic new molecular entities: 1986–2014. Nature Reviews Drug Discovery, 14(2), 83. https://www.doi.org/10.1038/nrd4535

Ministry of Health, Labour and Welfare. (2002). Pharmaceutical Industry Vision (in Japanese). Retrieved from https://www.mhlw.go.jp/shingi/2002/08/dl/s0830-1c.pdf

Ministry of Health, Labour and Welfare. (2007a). Action Program for Promotion of the Safe Use of Generic Drugs (in Japanese). Retrieved from https://www.mhlw.go.jp/houdou/2007/10/dl/h1015-1a.pdf

Ministry of Health, Labour and Welfare. (2007b). New Pharmaceutical Industry Vision (in Japanese). Retrieved from https://www.mhlw.go.jp/houdou/2007/08/dl/h0830-1b.pdf

Ministry of Health, Labour and Welfare. (2012). Promotion of the Use of Generic Drugs (in Japanese). Retrieved from https://www.mhlw.go.jp/english/policy_report/

Ministry of Health, Labour and Welfare. (2013). Pharmaceutical Industry Vision 2013 (in Japanese). Retrieved from https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iryou/shinkou/dl/vision_2013a.pdf

Ministry of Health, Labour and Welfare. (2016a). Basic Policy for Fundamental Reform of the Drug Pricing System (in Japanese). Retrieved from https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000146567.pdf

Ministry of Health, Labour and Welfare. (2016b). Central Social Insurance Medical Council (in Japanese). Retrieved from https://www.mhlw.go.jp/stf/shingi2/0000142573.html

Ministry of Health, Labour and Welfare. (2018). Update of Drug Pricing System in Japan [Presentation]. Retrieved from https://www.mhlw.go.jp/content/11123000/000335166.pdf

Miraldo, M. (2009). Reference pricing and firms' pricing strategies. Journal of Health Economics, 28(1), 176-197.

Morioka, K., Takayama, A., & Narukawa, M. (2017). Investigation of Characteristics of Long-Selling Drugs in Japan. Regulatory Science of Medical Products, 7(3), 151-162. https://www.doi.org/10.14982/rsmp.7.151

Nakajima, R., & Aruga, A. (2017). Analysis of New Drug Pricing and Reimbursement for Antibody Agents for Cancer Treatment in Japan. Regulatory Science of Medical Products, 7(3), 173-184. https://www.doi.org/10.14982/RSMP.7.173

Nakamura, H. (2005). Toward construction of Japan's new drug pricing system: aiming at financially improving Japan's national health insurance system and at stimulating R&D activities of innovative drugs in Japan (in Japanese). Iryo To Shakai, 15(1), 97-109.

Nakamura, H. (2007). Perspectives on structural changes in the pharmaceutical industry and new types of M&A and alliance: from the viewpoint of consistency between structural changes and the existing business model (in Japanese). Iryo To Shakai, 17(1), 39-53.

Nakamura, H., & Wakutsu N. (2019). Reducing pharmaceutical reimbursement price risk to lower national health expenditures without lowering R&D incentives. International Journal of Economic Policy Studies, 13(1), 75-88. https://www.doi.org/10.1007/s42495-018-0002-7

Nambu, T. (1997). The industrial organization of pharmaceuticals: the consequences of price regulation in Japan (in Japanese). Iryo To Shakai, 7(1), 3-15.

Patterson, J. A., & Carroll, N. V. (2020). Should the United States government regulate prescription prices? A critical review. Research in Social and Administrative Pharmacy, 16(5), 717-723. https://www.doi.org/10.1016/j.sapharm.2019.06.010

Penner-Hahn, J., & Shaver, J. M. (2005). Does international research and development increase patent output? An analysis of Japanese pharmaceutical firms. Strategic Management Journal, 26(2), 121-140. https://www.doi.org/10.1002/smj.436

Pharmaceuticals and Medical Devices Agency. (2007). Basic Principles on Global Clinical Trials. Retrieved from https://www.pmda.go.jp/files/000153265.pdf

Pharmaceuticals and Medical Devices Agency. (2014a). Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials. Retrieved from https://www.pmda.go.jp/files/000157777.pdf

Pharmaceuticals and Medical Devices Agency. (2014b). Guidance for Establishing Safety in First-in-Human Studies during Drug Development (in Japanese). Retrieved from https://www.pmda.go.jp/files/000208201.pdf

Pharmaceuticals and Medical Devices Agency. (2018). Drug Lag Estimation (in Japanese). Retrieved from https://www.pmda.go.jp/files/000233084.pdf

Pisani, N., Garcia-Bernardo, J., & Heemskerk, E. (2020). Does it pay to be a multinational? A large-sample, cross-national replication assessing the multinationality-performance relationship. Strategic Management Journal, 41(1), 152-172. https://www.doi.org/10.1002/smj.3087

Porter, M. E., & van der Linde, C. (1995). Toward a New Conception of the Environment-Competitiveness Relationship. Journal of Economic Perspectives, 9(4), 97-118. https://www.doi.org/10.1257/jep.9.4.97

Ridley, D. B. (2007). International Price Comparisons for Novel and Follow‐on Drugs. Value in Health, 10(6), 510-511. https://www.doi.org/10.1111/j.1524-4733.2007.00238.x

Ringel, M. S., & Choy, M. K. (2017). Do large mergers increase or decrease the productivity of pharmaceutical R&D? Drug Discovery Today, 22(12), 1749-1753. https://www.doi.org/10.1016/j.drudis.2017.06.002

Rokuda, M., Matsumaru, N., & Tsukamoto, K. (2018). Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan. Clinical Therapeutics, 40(2), 284-295. https://www.doi.org/10.1016/j.clinthera.2017.12.010

Roughead, E. E., Lopert, R., & Sansom, L. N. (2007). Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States. Value in Health, 10(6), 514-520. https://www.doi.org/10.1111/j.1524-4733.2007.00206.x

Ryu, W., Reuer, J. J., & Brush, T. H. (2020). The effects of multimarket contact on partner selection for technology cooperation. Strategic Management Journal, 41(2), 267-289. https://www.doi.org/10.1002/smj.3106

Sams-Dodd, F. (2007). Research & market strategy: how choice of drug discovery approach can affect market position. Drug Discovery Today, 12(7-8), 314-318. https://www.doi.org/10.1016/j.drudis.2007.02.014

Shibata, S., & Suzuki, T. (2018) The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classes. Journal of Generic Medicines, 14(2), 70-80. https://www.doi.org/10.1177/1741134317737344

Shibata, S., Chiba, K., & Suzuki, T. (2017a). Downward trend in review time in Pharmaceuticals and Medical Devices Agency in Japan under the unique premium rewards system of the Japanese pharmaceutical market. American Journal of Pharmacy and Health Research, 5(7), 25-36.

Shibata, S., Chiba, K., & Suzuki, T. (2017b). Downward trend in review time in Pharmaceuticals and Medical Devices Agency in Japan under the unique premium rewards system of the Japanese pharmaceutical market: 2nd report. American Journal of Pharmacy and Health Research, 5(7), 37-52.

Shibata, S., Uemura, R., & Suzuki T. (2016a). Comparative analysis between the top-selling drugs in the Japanese pharmaceutical market and those in the United States, the United Kingdom, France, and Germany. Therapeutic Innovation & Regulatory Science, 50(2), 221-227. https://www.doi.org/10.1177/2168479015604182

Shibata, S., Uemura, R., & Suzuki, T. (2016b). Evaluating the effectiveness of repricing for market expansion in the Japanese drug pricing system. Therapeutic Innovation & Regulatory Science, 50(6), 751-758. https://www.doi.org/10.1177/2168479016652927

Shibata, S., Uemura, R., & Suzuki, T. (2016c). Factors that affect the acquisition of reward premiums for promotion of innovative drug discovery in Japan. Therapeutic Innovation & Regulatory Science, 50(1), 56-65. https://www.doi.org/10.1177/2168479015596007

Shibata, S., Uemura, R., & Suzuki, T. (2016d). Impact of premium rewards for the promotion of innovative drug discovery on the Japanese pharmaceutical market: An analysis by therapeutic area. Therapeutic Innovation & Regulatory Science, 50(1), 49-55. https://www.doi.org/10.1177/2168479015600205

Shibata, S., Uemura, R., Chiba, K., & Suzuki, T. (2016). A comprehensive analysis of factors that contribute to conditional approval and all-case surveillance designations that subsequently lead to shortening of review times in Japan. Journal of Regulatory Science, 4(1), 1-9. https://www.doi.org/10.21423/jrs-v04n01p001

Shibata, S., Fukumoto, D., Suzuki, T., & Ozaki, K. (2020a). A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl–Hirschman Index. Therapeutic Innovation & Regulatory Science, 54(5), 1047-1055. https://www.doi.org/10.1007/s43441-020-00122-6

Shibata, S., Fukumoto, D., Suzuki, T., & Ozaki, K. (2020b). Analyzing upward deviation of actual vs predicted drug sales in Japan for a reasonable drug-pricing policy. Therapeutic Innovation & Regulatory Science, 54(3), 544-551. https://www.doi.org/10.1177/2168479019860123

Shibata, S., Kawaguchi, H., Uemura, R., & Suzuki, T. (2016). Emerging growth of orphan drugs for neurological diseases in Japan: potential benefits for both patients and pharmaceutical companies. Journal of Regulatory Science, 4(3), 7-13. https://www.doi.org/10.21423/jrs-v04n03p007

Shibata, S., Matsushita, M., Saito, Y., & Suzuki, T. (2017). Optimal anti-cancer drug profiles for effective penetration of the anti-cancer drug market by generic drugs in Japan. Therapeutic Innovation & Regulatory Science, 52(4), 442-448. https://www.doi.org/10.1177/2168479017749513

Shibata, S., Matsushita, M., Saito, Y., & Suzuki, T. (2018). Anticancer drug prescription patterns in Japan: future directions in cancer therapy. Therapeutic Innovation & Regulatory Science, 52(6), 718-723. https://www.doi.org/10.1177/2168479017751404

Shibata, S., Wayama, Y., Tsuyuki, A., Matsushita, M., Chiba, K., Matsuki, E., Okamoto, S., & Suzuki, T. (2017). An empirical study of the prescription pattern of drugs for hematological malignancies in Japan from 2010-2014. Biological and Pharmaceutical Bulletin, 40(6), 894-901. https://www.doi.org/10.1248/bpb.b17-00111

Shirotani, M., Kurokawa, T., & Chiba, K. (2014). Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan. The Journal of Clinical Pharmacology, 54(7), 753-764. https://www.doi.org/10.1002/jcph.273

Shirotani, M., Suwa, T., Kurokawa, T., & Chiba, K. (2014). Efficient clinical trials in Japan: bridging studies versus participation in global clinical trials. The Journal of Clinical Pharmacology, 54(4), 438-445. https://www.doi.org/10.1002/jcph.216

Suzuki, M., & Nakamura, H. (1998). German reference price system and the effects on drug prices, prescription volume, and R&D incentives (in Japanese). Iryo To Shakai, 8(3), 17-38.

Takayama, A., Kobayashi, E., Nakamura, T., & Narukawa, M. (2017). Quantitative assessment of premium rates for clinical usefulness in new drug price calculation in Japan. Therapeutic Innovation & Regulatory Science, 51(5), 582-588. https://www.doi.org/10.1177/2168479017696270

Takayama, A., & Narukawa, M. (2016a). Investigation of factors affecting the degree of price gap between the national health insurance reimbursement price and the actual market price of new drugs (in Japanese). Regulatory Science of Medical Products, 6(3), 295-305. https://www.doi.org/10.14982/rsmp.6.295

Takayama, A., & Narukawa, M. (2016b). Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs. Therapeutic Innovation & Regulatory Science, 50}(3), 361-367. https://www.doi.org/10.1177/2168479015619202

Takayama, A., & Narukawa, M. (2017). Comparison of New Drug Accessibility and Price Between Japan and Major European Countries. Therapeutic Innovation & Regulatory Science, 51(5), 604-611. https://www.doi.org/10.1177/2168479017706716

Teramae, F., Makino, T., Lim, Y., Sengoku, S., & Kodama, K. (2020). International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies. Sustainability, 12(3), 867. https://www.doi.org/10.3390/su12030867

Thomas, L. G., III. (2004). Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industry. Strategic Management Journal, 25(8-9), 865-886. https://www.doi.org/10.1002/smj.420

Thomke, S., & Kuemmerle, W. (2002). Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery. Strategic Management Journal, 23(7), 619-635. https://www.doi.org/10.1002/smj.242

Thakor, R. T., Anaya, N., Zhang, Y., Vilanilam, C., Siah, K. W., Wong, C. H., & Lo, A. W. (2017). Just how good an investment is the biopharmaceutical sector? Nature Biotechnology, 35(12), 1149-1157. https://www.doi.org/10.1038/nbt.4023

Tominaga, T., Ando, Y., & Kondo, T. (2012). International Vision and Strategy for Drug Regulatory Authority: The PMDA's International Vision. Clinical Pharmacology & Therapeutics, 92(3), 349-351. https://www.doi.org/10.1038/clpt.2012.90

Ueno, T., Asahina, Y., Tanaka, A., Yamada, H., Nakamura, M., & Uyama, Y. (2014). Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan. Clinical Pharmacology & Therapeutics, 95(5), 533-541. https://www.doi.org/10.1038/clpt.2013.223

Wakutsu, N., & Nakamura, H. (2015a). Analyzing the benefits from new NHI drug pricing system in Japan: factor decomposition and simulation (in Japanese). Iryo To Shakai, 25(2), 205-220. https://www.doi.org/10.4091/iken.25.205

Wakutsu, N., & Nakamura, H. (2015b). New NHI drug-pricing system in Japan: incentives for R&D and budget neutrality. International Journal of Economic Policy Studies, 10(1), 1-12. https://www.doi.org/10.1007/BF03405759

Wettstein, D. J., & Boes, S. (2019). Effectiveness of national pricing policies for patent-protected pharmaceuticals in the OECD: a systematic literature review. Applied Health Economics and Health Policy, 17(2), 143-162. https://www.doi.org/10.1007/s40258-018-0437-z

Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20(2), 273-286. https://www.doi.org/10.1093/biostatistics/kxx069

Wright, D. J. (2004). The drug bargaining game: pharmaceutical regulation in Australia. Journal of Health Economics, 23(4), 785-813. https://www.doi.org/10.1016/j.jhealeco.2003.11.003

Xin, Y. J., Hubbard-Lucey, V. M., & Tang, J. (2019). Immuno-oncology drug development goes global. Nature Reviews Drug discovery, 18(12), 899-900. https://www.doi.org/10.1038/d41573-019-00167-9

Yamashita, K., Kaneko, M., & Narukawa, M. (2019). A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers. Clinical Pharmacology & Therapeutics, 105(1), 153-160. https://www.doi.org/10.1002/cpt.1136






Review Articles

How to Cite

Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research. (2020). Journal of Regulatory Science, 8, 1-13. https://doi.org/10.21423/JRS-V08SHOYO